To wake up cancer stem cells, or to let them sleep, that is the question

Cancer Science

Volumn 107, Issue 7, 2016, Pages 875-881

  Takeishi, Shoichiro ^a,b   Nakayama, Keiichi I ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

Cancer stem cell; Fbxw7; leukemia stem cell; quiescence; stem cell niche

Indexed keywords

ALPHA INTERFERON; ANTINEOPLASTIC AGENT; CARRIER PROTEINS AND BINDING PROTEINS; DASATINIB; DNA BINDING PROTEIN; DNA BINDING PROTEIN INHIBITOR; F BOX AND WD40 REPEAT DOMAIN CONTAINING 7; F BOX PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB; INHIBITOR OF DIFFERENTIATION PROTEIN; NILOTINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; PROMYELOCYTIC LEUKEMIA PROTEIN; PROTEIN INHIBITOR; S PHASE KINASE ASSOCIATED PROTEIN 2; STROMAL CELL DERIVED FACTOR 1; UNCLASSIFIED DRUG;

APOPTOSIS; CANCER RECURRENCE; CANCER STEM CELL; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; GENE SILENCING; HUMAN; METASTASIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT;

EID: 84978898661     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12958     Document Type: Review

References (49)

1. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014; 14: 275–91.
2. Yoshida GJ, Saya H. Therapeutic strategies targeting cancer stem cells. Cancer Sci 2016; 107: 5–11.
3. Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol 2010; 4: 443–50.
4. Plaks V, Kong N, Werb Z. The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell 2015; 16: 225–38.
5. Mazza M, Pelicci PG. Is PML a tumor suppressor? Front Oncol 2013; 3: 174.
6. Mathews V, George B, Lakshmi KM et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood 2006; 107: 2627–32.
7. Aronson SM. Arsenic and old myths. R I Med 1994; 77: 233–4.
8. Ito K, Bernardi R, Morotti A et al. PML targeting eradicates quiescent leukaemia-initiating cells. Nature 2008; 453: 1072–8.
9. Ito K, Carracedo A, Weiss D et al. A PML-PPAR-delta pathway for fatty acid oxidation regulates hematopoietic stem cell maintenance. Nat Med 2012; 18: 1350–8.
10. Yoshimura Y, Shiino A, Muraki K et al. Arsenic trioxide sensitizes glioblastoma to a myc inhibitor. PLoS ONE 2015; 10: e0128288.
11. Bansal N, Farley NJ, Wu L, Lewis J, Youssoufian H, Bertino JR. Darinaparsin inhibits prostate tumor-initiating cells and Du145 xenografts and is an inhibitor of hedgehog signaling. Mol Cancer Ther 2015; 14: 23–30.
12. Lasorella A, Benezra R, Iavarone A. The ID proteins: master regulators of cancer stem cells and tumour aggressiveness. Nat Rev Cancer 2014; 14: 77–91.
13. O'Brien CA, Kreso A, Ryan P et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 2012; 21: 777–92.
14. Nakayama KI, Nakayama K. Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 2006; 6: 369–81.
15. Takeishi S, Matsumoto A, Onoyama I, Naka K, Hirao A, Nakayama KI. Ablation of Fbxw7 eliminates leukemia-initiating cells by preventing quiescence. Cancer Cell 2013; 23: 347–61.
16. Takeishi S, Nakayama KI. Role of Fbxw7 in the maintenance of normal stem cells and cancer-initiating cells. Br J Cancer 2014; 111: 1054–9.
17. Matsuoka S, Oike Y, Onoyama I et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. Genes Dev 2008; 22: 986–91.
18. Li Y, Qi Y, Huang TH, Yamahara J, Roufogalis BD. Pomegranate flower: a unique traditional antidiabetic medicine with dual PPAR-alpha/-gamma activator properties. Diabetes Obes Metab 2008; 10: 10–7.
19. Prost S, Relouzat F, Spentchian M et al. Erosion of the chronic myeloid leukaemia stem cell pool by PPARgamma agonists. Nature 2015; 525: 380–3.
20. Smith TJ, Khatcheressian J, Lyman GH et al. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187–205.
21. Jorgensen HG, Copland M, Allan EK et al. Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006; 12: 626–33.
22. Gallipoli P, Stobo J, Heaney N et al. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. Br J Haematol 2013; 163: 674–6.
23. Saito Y, Uchida N, Tanaka S et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol 2010; 28: 275–80.
24. Ishikawa F, Yoshida S, Saito Y et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol 2007; 25: 1315–21.
25. Wilson A, Laurenti E, Oser G et al. Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair. Cell 2008; 135: 1118–29.
26. Lowenberg B, van Putten W, Theobald M et al. Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia. N Engl J Med 2003; 349: 743–52.
27. Amadori S, Suciu S, Jehn U et al. Use of glycosylated recombinant human G-CSF (lenograstim) during and/or after induction chemotherapy in patients 61 years of age and older with acute myeloid leukemia: final results of AML-13, a randomized phase-3 study. Blood 2005; 106: 27–34.
28. Buchner T, Berdel WE, Hiddemann W. Priming with granulocyte colony-stimulating factor–relation to high-dose cytarabine in acute myeloid leukemia. N Engl J Med 2004; 350: 2215–6.
29. Estey EH, Thall PF, Pierce S et al. Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/− all-trans retinoic acid +/− granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 1999; 93: 2478–84.
30. Milligan DW, Wheatley K, Littlewood T, Craig JI, Burnett AK, Group NHOCS. Fludarabine and cytosine are less effective than standard ADE chemotherapy in high-risk acute myeloid leukemia, and addition of G-CSF and ATRA are not beneficial: results of the MRC AML-HR randomized trial. Blood 2006; 107: 4614–22.
31. Ohno R, Naoe T, Kanamaru A et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Kohseisho Leukemia Study Group. Blood 1994; 83: 2086–92.
32. Talpaz M, Mercer J, Hehlmann R. The interferon-alpha revival in CML. Ann Hematol 2015; 94(Suppl 2): S195–207.
33. Essers MA, Offner S, Blanco-Bose WE et al. IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 2009; 458: 904–8.
34. Sato T, Onai N, Yoshihara H, Arai F, Suda T, Ohteki T. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 2009; 15: 696–700.
35. Pietras EM, Lakshminarasimhan R, Techner JM et al. Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 2014; 211: 245–62.
36. Nagasawa T, Kikutani H, Kishimoto T. Molecular cloning and structure of a pre-B-cell growth-stimulating factor. Proc Natl Acad Sci USA 1994; 91: 2305–9.
37. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. Nature 2014; 505: 327–34.
38. Zeng Z, Shi YX, Samudio IJ et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood 2009; 113: 6215–24.
39. Nervi B, Ramirez P, Rettig MP et al. Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood 2009; 113: 6206–14.
40. Weisberg E, Azab AK, Manley PW et al. Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinib. Leukemia 2012; 26: 985–90.
41. Uy GL, Rettig MP, Motabi IH et al. A phase 1/2 study of chemosensitization with the CXCR4 antagonist plerixafor in relapsed or refractory acute myeloid leukemia. Blood 2012; 119: 3917–24.
42. Chan CH, Morrow JK, Li CF et al. Pharmacological inactivation of Skp2 SCF ubiquitin ligase restricts cancer stem cell traits and cancer progression. Cell 2013; 154: 556–68.
43. Agarwal A, Bumm TG, Corbin AS et al. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease. Blood 2008; 112: 1960–70.
44. Rodriguez S, Wang L, Mumaw C et al. The SKP2 E3 ligase regulates basal homeostasis and stress-induced regeneration of HSCs. Blood 2011; 117: 6509–19.
45. Foo J, Drummond MW, Clarkson B, Holyoake T, Michor F. Eradication of chronic myeloid leukemia stem cells: a novel mathematical model predicts no therapeutic benefit of adding G-CSF to imatinib. PLoS Comput Biol 2009; 5: e1000503.
46. Mohrin M, Bourke E, Alexander D et al. Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 2010; 7: 174–85.
47. Beerman I, Seita J, Inlay MA, Weissman IL, Rossi DJ. Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. Cell Stem Cell 2014; 15: 37–50.
48. Gorre ME, Mohammed M, Ellwood K et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–80.
49. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012; 22: 457–72.